Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Authors
Keywords
Metastatic melanoma, Checkpoint inhibitors, Biomarker, Immune response, Antibodies, Melanocyte differentiation antigens, Cancer/testis antigens, gp100, TRP1, TRP2, MART1, NY-ESO-1
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-20
DOI
10.1186/s40425-019-0523-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1
- (2018) G.M. Haag et al. EUROPEAN JOURNAL OF CANCER
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
- (2017) Giulia Chiaruttini et al. OncoImmunology
- Evolution of Salmonella Typhi outer membrane protein-specific T and B cell responses in humans following oral Ty21a vaccination: A randomized clinical trial
- (2017) Juan Manuel Carreño et al. PLoS One
- Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
- (2016) S Diem et al. BRITISH JOURNAL OF CANCER
- Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
- (2016) Kelly D Moynihan et al. NATURE MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
- (2015) M.H. Geukes Foppen et al. Molecular Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
- (2014) Sander Kelderman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor infiltrating B-cells are increased in prostate cancer tissue
- (2014) Jason R Woo et al. Journal of Translational Medicine
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer
- (2012) Rin Yamaguchi et al. HUMAN PATHOLOGY
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
- (2012) S. S. Kwek et al. JOURNAL OF IMMUNOLOGY
- Fiji: an open-source platform for biological-image analysis
- (2012) Johannes Schindelin et al. NATURE METHODS
- TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
- (2012) Pia Kvistborg et al. OncoImmunology
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies
- (2011) Amy E. Gilbert et al. PLoS One
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients
- (2009) C. M. Vajdic et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Spontaneous regression of metastases from melanoma: review of the literature
- (2009) Louise Vennegaard Kalialis et al. MELANOMA RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started